Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Total Current Liabilities (2017 - 2025)

Autolus Therapeutics' Total Current Liabilities history spans 9 years, with the latest figure at $73.4 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 20.9% year-over-year to $73.4 million; the TTM value through Dec 2025 reached $73.4 million, up 20.9%, while the annual FY2025 figure was $73.4 million, 20.9% up from the prior year.
  • Total Current Liabilities reached $73.4 million in Q4 2025 per AUTL's latest filing, down from $83.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $83.1 million in Q3 2025 to a low of $28.6 million in Q4 2021.
  • Average Total Current Liabilities over 5 years is $48.9 million, with a median of $44.0 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: fell 15.11% in 2021, then skyrocketed 66.61% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $28.6 million in 2021, then skyrocketed by 62.4% to $46.4 million in 2022, then dropped by 3.51% to $44.7 million in 2023, then skyrocketed by 35.78% to $60.7 million in 2024, then increased by 20.9% to $73.4 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Total Current Liabilities are $73.4 million (Q4 2025), $83.1 million (Q3 2025), and $68.2 million (Q2 2025).